Did you miss "Mad Money" on CNBC? If so, here are some of Jim Cramer's top takeaways.
Sometimes a company can have a great long-term story, but management fails to deliver. That's why Zimmer Biomet (ZBH) - Get Report saw its shares head higher when CEO David Dvorak announced he would be stepping down from the company.
Cramer said it's been two years since Zimmer merged with Biomet, a deal that was supposed to ignite growth and rival the performance of industry leaders like Stryker (SYK) - Get Report . Back then, everyone was excited about the deal, Cramer included.
But in the two years since the deal closed, Zimmer has delivered sub-optimal performance, with organic growth of only 1.3%, far short of the 4% the company estimated. Zimmer's last pre-announcement was also at the low end of range, signaling that a charge of fortunes was not in the cards.
But now that activist Janis Partners has taken a stake in the company, and CEO Dvorak has stepped aside, perhaps things can change at Zimmer Biomet. Cramer said he's not willing to recommend the stock quite yet, but the news is encouraging.
Cramer and the AAP team say they are keeping a close eye on oil and Schlumberger's (SLB) - Get Report earnings report. Get in on the conversation with a free trial subscription to Action Alerts PLUS.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To read a full recap of this episode of "Mad Money," click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer's Action Alerts PLUS had a position in SLB.